Clinical trial NCT02308085: Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer
Official title: A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Early Breast Cancer
Keywords: Premenopausal
endocrine responsive
Breast
Pregnancy
Lead sponsor: ETOP IBCSG Partners Foundation
Sponsor class: NETWORK
Collaborators: name: Alliance for Clinical Trials in Oncology
name: Canadian Cancer Trials Group
name: Breast International Group
First posted: 2014-12-04
Enrollment: 518
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 42
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The best available evidence suggests that pregnancy after breast cancer does not increase a woman's risk of developing a recurrence from her breast cancer. In particular, the most recent data suggest that this is the case also in women with a hormone receptor-positive breast cancer. There is also no indication of increased risk for delivery complications or for the newborn. The aim of the study is to investigate if temporary interruption of endocrine therapy, with the goal to permit pregnancy, is associated with a higher risk of breast cancer recurrence.The study aims also to evaluate different specific indicators related to fertility, pregnancy and breast cancer biology in young women. A psycho-oncological companion study on fertility concerns, psychological well-being and decisional conflicts will be conducted in interested Centers.

Detailed description: Recent decades have witnessed a delay in childbearing for a variety of reasons including cultural, educational, and professional. As a consequence, breast cancer in young women often occurs before the completion of reproductive plans. Infertility has a significant impact on quality of life, resulting in substantial distress in younger women with breast cancer and influencing treatment decisions in a consistent proportion of patients.The best available evidence suggests that pregnancy after breast cancer does not increase a woman's risk of developing a recurrence.For women desiring pregnancy after a breast cancer, 5-10 years of endocrine therapy may substantially reduce the chance of conception; however, a shorter duration of endocrine therapy in this population has not been studied in a prospective manner.

Birth outcome after breast cancer has not been shown to be different from that of the normal population, but increased risks of delivery complications, cesarean section, preterm birth and low birth weight have been reported.

Endocrine agents are potentially teratogenic: taking into account their median half-life, waiting 3 months after their interruption before attempting conception is considered safe.

The limited evidence available on breastfeeding after breast cancer reports successful lactation from the treated breast in approximately 30% of women without detrimental effect on survival. No prospective definitive data are available.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 and ≤ 42 years at enrollment.
* Has received adjuvant endocrine therapy (SERM alone, GnRH analogue plus SERM or AI) for ≥18 months but ≤30 months for early breast cancer.

Note: Patients who have received neo/adjuvant endocrine treatment within a clinical trial and patients who have received pharmaco-prevention are eligible.

* The adjuvant endocrine therapy must have stopped within 1 month prior to enrollment.
* Patient wishes to become pregnant. Note: Patients who have undergone oocyte/embryo/ovarian tissue cryopreservation at breast cancer diagnosis and/or have a previous history of assisted reproductive technology (ART) are eligible.
* Breast cancer for which patient is receiving endocrine therapy must have been histologically-proven stage I-III, endocrine-responsive (i.e., estrogen and/or progesterone receptor positive, according to local definition of positive, determined using immunohistochemistry (IHC)), and treated with curative intent.

Note:

* Patients with synchronous bilateral invasive breast cancer (diagnosed histologically within 2 months) are eligible.
* Patient with invasive breast cancer or synchronous bilateral invasive breast cancer (diagnosed histologically within 2 months) during pregnancy are eligible.
* Patients with BRCA1/2 mutations are eligible.
* Patients could have received neo/adjuvant chemotherapy, or other systemic therapy (e.g., neo/adjuvant HER2-targeted therapy) according to institutional policy and patient's desire.
* Patient must be premenopausal at breast cancer diagnosis, as determined locally and documented in patient record.
* Patient must be without clinical evidence of loco-regional and distant disease, as evaluated according to institutional assessment standards and documented in the patient record.
* Written informed consent (IC) for trial participation must be signed and dated by the patient and the investigator prior to enrollment.
* Written consent to biological material submission, indicating the patient has been informed of and agrees to tissue and blood material use, transfer and handling, must be signed and dated by the patient and the investigator prior to any procedures specific for this trial.
* The patient has been informed of and agrees to data transfer and handling, in accordance with national data protection guidelines.
* Patient must be accessible for follow-up.

Exclusion Criteria:

* Post-menopausal patients at BC diagnosis, as determined locally.
* History of hysterectomy, bilateral oophorectomy or ovarian irradiation.
* Patients with current local, loco-regional relapse and/or distant metastatic breast cancer.
* Patients with a history of prior (ipsi- and/or contralateral) invasive BC.
* Patients with previous or concomitant non-breast invasive malignancy.
* Exceptions are limited exclusively to patients with the following previous malignancies, if adequately treated: basal or squamous cell carcinoma of the skin, in situ non-breast carcinoma, contra- or ipsilateral in situ breast carcinoma, stage Ia carcinoma of the cervix.
* Concurrent disease or condition that would make the patient inappropriate for study participation or any serious medical disorder that would interfere with the patient's safety.
* Patients with a history of noncompliance to medical treatments and/or considered potentially unreliable.
* Patients with psychiatric, addictive, or any disorder that would prevent compliance with protocol requirements.

Primary outcomes:
measure: Breast Cancer free interval (BCFI)
timeFrame: From enrollment until the first invasive BC event, assessed up to 14 years
Secondary outcomes:
measure: Information on Menstruation recovery and pattern
timeFrame: Up to 24 months after enrollment
measure: Pregnancy rate (determined by pregnancy test)
timeFrame: Up to 24 months after enrollment
measure: Pregnancy outcome
timeFrame: Up to 33 months after enrollment
measure: Offspring outcome
timeFrame: Up to 33 months after enrollment
measure: Breastfeeding pattern
timeFrame: Up to 36 months after enrollment
measure: Use of assisted reproductive Technology (ART)
timeFrame: Up to 24 months after enrollment
measure: Distant recurrence-free interval (DRFI)
timeFrame: Time from enrollment in the study to the first breast cancer recurrence in a distant site, assessed up to 14 years
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Cedars Sinai Medical Centre
state: California
city: Palo Alto
country: United States
facility: Stanford Cancer Institute
state: California
city: San Diego
country: United States
facility: Sharp Memorial Hospital
state: California
city: Aurora
country: United States
facility: University of Colorado Cancer Centre - Anschutz Cancer Pavilion
state: Colorado
city: Boulder
country: United States
facility: Rocky Mountain Cancer Center
state: Colorado
city: Denver
country: United States
facility: SCL Health Saint Joseph Hospital
state: Colorado
city: Fort Collins
country: United States
facility: Poudre Valley Hospital
state: Colorado
city: Derby
country: United States
facility: Smilow Cancer Hospital-Derby Care Center
state: Connecticut
city: Fairfield
country: United States
facility: Smilow Cancer Hospital Care Center-Fairfield
state: Connecticut
city: Hartford
country: United States
facility: Smilow Cancer Hospital Care Center at Saint Francis
state: Connecticut
city: New Haven
country: United States
facility: Yale University - Yale Cancer Centre
state: Connecticut
city: North Haven
country: United States
facility: Yale-New Haven Hospital North Haven Medical Center
state: Connecticut
city: Orange
country: United States
facility: Smilow Cancer Hospital-Orange Care Center
state: Connecticut
city: Torrington
country: United States
facility: Smilow Cancer Hospital-Torrington Care Center
state: Connecticut
city: Trumbull
country: United States
facility: Smilow Cancer Hospital Care Center-Trumbull
state: Connecticut
city: Waterbury
country: United States
facility: Smilow Cancer Hospital-Waterbury Care Center
state: Connecticut
city: Newark
country: United States
facility: Helen F. Graham Cancer Center
state: Delaware
city: Newark
country: United States
facility: Christiana Care Health System-Christiana Hospital
state: Delaware
city: Newport
country: United States
facility: Medical Oncology Hematology Consultants PA
state: Delaware
city: Newport
country: United States
facility: Regional Hematology Oncology Practice Associates
state: Delaware
city: Washington, D.C.
country: United States
facility: Georgetown University Hospital
state: District of Columbia
city: Washington
country: United States
facility: Sibley Memorial Hospital
state: District of Columbia
city: Atlanta
country: United States
facility: Emory University Hospital Midtown
state: Georgia
city: Atlanta
country: United States
facility: Emory University
state: Georgia
city: Honolulu
country: United States
facility: Straub Clinic and Hospital
state: Hawaii
city: Honolulu
country: United States
facility: OnCare Hawaii Inc - POB I
state: Hawaii
city: Honolulu
country: United States
facility: Queen's Medical Centre
state: Hawaii
city: Honolulu
country: United States
facility: OnCare Hawaii-Kuakini
state: Hawaii
city: Chicago
country: United States
facility: John H Stroger Jr Hospital of Cook County
state: Illinois
city: Danville
country: United States
facility: Carle on Vermilion
state: Illinois
city: Effingham
country: United States
facility: Carle Physician Group - Effingham
state: Illinois
city: Evanston
country: United States
facility: NorthShore University HealthSystem-Evanston Hospital
state: Illinois
city: Evanston
country: United States
facility: Northwestern University
state: Illinois
city: Glenview
country: United States
facility: NorthShore University Health System - Glenbrook Hospital
state: Illinois
city: Highland Park
country: United States
facility: NorthShore Unversity Health System - Highland Park Hospital
state: Illinois
city: Mattoon
country: United States
facility: Mattoon Charleston Primary Care
state: Illinois
city: Skokie
country: United States
facility: NorthShore Medical Centre
state: Illinois
city: Urbana
country: United States
facility: Carle Cancer Centre
state: Illinois
city: Urbana
country: United States
facility: The Carle Foundation Hospital
state: Illinois
city: Indianapolis
country: United States
facility: Indiana University
state: Indiana
city: Baltimore
country: United States
facility: Greater Baltimore Medical Centre
state: Maryland
city: Baltimore
country: United States
facility: Johns Hopkins University
state: Maryland
city: Boston
country: United States
facility: Dana Farber Cancer Institute
state: Massachusetts
city: Ann Arbor
country: United States
facility: Saint Joseph Mercy Hospital
state: Michigan
city: Brighton
country: United States
facility: IHA Hematology Consultants-Brighton
state: Michigan
city: Brighton
country: United States
facility: Saint Joseph Mercy Hospital - Brighton
state: Michigan
city: Canton
country: United States
facility: IHA Hematology Consultants-Canton
state: Michigan
city: Canton
country: United States
facility: Saint Joseph Mercy Hospital- Canton
state: Michigan
city: Chelsea
country: United States
facility: IHA Hematology Consultants-Chelsea
state: Michigan
city: Chelsea
country: United States
facility: Saint Joseph Mercy Hospital - Chelsea
state: Michigan
city: Ypsilanti
country: United States
facility: IHA Hematology Oncology Consultants-Ann Arbor
state: Michigan
city: Bemidji
country: United States
facility: Sanford Clinic North - Bemidji
state: Minnesota
city: Coon Rapids
country: United States
facility: Mercy Hospital
state: Minnesota
city: Duluth
country: United States
facility: Essentia Health Cancer Center
state: Minnesota
city: Edina
country: United States
facility: Fairview Southdale Hospital
state: Minnesota
city: Maplewood
country: United States
facility: St John's Hospital
state: Minnesota
city: Minneapolis
country: United States
facility: Abbott-Northwestern Hospital, 800 East 28th Street
state: Minnesota
city: Minneapolis
country: United States
facility: Hennepin County Medical Center - Cancer Center
state: Minnesota
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: Saint Louis Park
country: United States
facility: Park Nicollet Methodist Hospital
state: Minnesota
city: St Paul
country: United States
facility: Regions Hospital
state: Minnesota
city: Saint Louis
country: United States
facility: Missouri Baptist Medical Center
state: Missouri
city: Bozeman
country: United States
facility: Bozeman Deaconess Hospital
state: Montana
city: Lebanon
country: United States
facility: Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center
state: New Hampshire
city: Albuquerque
country: United States
facility: University of New Mexico Cancer Center
state: New Mexico
city: Bronx
country: United States
facility: Montefiore Medical Center - Einstein Campus, 1695 Eastchester Road
state: New York
city: Bronx
country: United States
facility: Montefiore Medical Center-Weiler Hospital
state: New York
city: Bronx
country: United States
facility: Montefiore Medical Center - Moses Campus, 111 East 210th Street
state: New York
city: New York
country: United States
facility: Weill Medical College of Cornell University
state: New York
city: Syracuse
country: United States
facility: SUNY Upstate Medical University
state: New York
city: White Plains
country: United States
facility: Dickstein Cancer Treatment Centre
state: New York
city: Chapel Hill
country: United States
facility: UNC Lineberger Comprehensive Cancer Center
state: North Carolina
city: Clinton
country: United States
facility: Southeastern Medical Oncology Centre
state: North Carolina
city: Goldsboro
country: United States
facility: Southeastern Medical Oncology Centre
state: North Carolina
city: Hendersonville
country: United States
facility: Margaret R Pardee Memorial Hospital
state: North Carolina
city: Jacksonville
country: United States
facility: Southeastern Medical Oncology Centre
state: North Carolina
city: Wilson
country: United States
facility: Southeastern Medical Oncology Centre
state: North Carolina
city: Bismarck
country: United States
facility: Sanford Bismark Medical Centre
state: North Dakota
city: Fargo
country: United States
facility: Sanford Roger Maris Cancer Centre
state: North Dakota
city: Fargo
country: United States
facility: Sanford Medical Centre
state: North Dakota
city: Cleveland
country: United States
facility: Case Western Reserve University
state: Ohio
city: Columbus
country: United States
facility: Ohio State University
state: Ohio
city: Orange Village
country: United States
facility: Chagrin Highlands
state: Ohio
city: Pittsburgh
country: United States
facility: UPMC-Magee Womens Hospital
state: Pennsylvania
city: Providence
country: United States
facility: Women and Infants Hospital of Rhode Island
state: Rhode Island
city: Greenville
country: United States
facility: Greenville Health System Cancer Institute-Butternut
state: South Carolina
city: Greenville
country: United States
facility: Greenville Health System Cancer Institute-Faris
state: South Carolina
city: Greenville
country: United States
facility: Greenville Health System Cancer Institute-Eastside
state: South Carolina
city: Greer
country: United States
facility: Greenville Health System Cancer Institute-Greer
state: South Carolina
city: Seneca
country: United States
facility: Greenville Health System Cancer Institute-Seneca
state: South Carolina
city: Spartanburg
country: United States
facility: Spartanburg Medical Center
state: South Carolina
city: Spartanburg
country: United States
facility: Greenville Health System Cancer Institute-Spartanburg
state: South Carolina
city: Sioux Falls
country: United States
facility: Sanford Cancer Centre Oncology Clinic
state: South Dakota
city: Sioux Falls
country: United States
facility: Sanford USD Medical Centre - Sioux Falls
state: South Dakota
city: Laredo
country: United States
facility: Doctor's Hospital of Laredo
state: Texas
city: Salt Lake City
country: United States
facility: Huntsman Cancer Institute / University of Utah
state: Utah
city: Burlington
country: United States
facility: University of Vermont Medical Centre
state: Vermont
city: Mechanicsville
country: United States
facility: Bon Secours Memorial Regional Medical Centre
state: Virginia
city: Midlothian
country: United States
facility: Bon Secours Saint Francis Medical Centre
state: Virginia
city: Richmond
country: United States
facility: Bon Secours Saint Mary's Hospital
state: Virginia
city: Seattle
country: United States
facility: Fred Hutchinson Cancer Research Center
state: Washington
city: Seattle
country: United States
facility: Seattle Cancer Care Alliance
state: Washington
city: Seattle
country: United States
facility: University of Washington Medical Center
state: Washington
city: Perth
country: Australia
facility: St John of God Subiaco Hospital
state: Western Australia
city: Graz
country: Austria
facility: Univ. Klinik f. Frauenheilkunde u. Geburtshilfe
city: Innsbruck
country: Austria
facility: Univ. Klinik f. Frauenheilkunde Innsbruck
city: Salzburg
country: Austria
facility: LKH Salzburg
city: Vienna
country: Austria
facility: Med. Univ. Klinik f. Chir
city: Brussels
country: Belgium
facility: Cliniques Universitaires Saint-Luc
city: Brussels
country: Belgium
facility: Cliniques Universitaires Saint-Luc Brussels
city: Brussels
country: Belgium
facility: Institut Jules Bordet
city: Leuven
country: Belgium
facility: UZ Leuven
city: Liege
country: Belgium
facility: C.H.U. Sart-Tilman
city: Namur
country: Belgium
facility: Clinique St.Elizabeth
city: Calgary
country: Canada
facility: Tom Baker Cancer Centre
state: Alberta
city: Vancouver
country: Canada
facility: Vancouver Cancer Centre
state: British Columbia
city: Toronto
country: Canada
facility: St Michael's Hospital
state: Ontario
city: Toronto
country: Canada
facility: Mount Sinai Hospital
state: Ontario
city: Toronto
country: Canada
facility: Odette Cancer Centre - Sunnybrook Health Sciences Centre
state: Ontario
city: Montréal
country: Canada
facility: CHUM - Centre Hospitalier de l'Universite de Montreal
state: Quebec
city: Quebec City
country: Canada
facility: CHA-Hopital Du St-Sacrement
state: Quebec
city: Sherbrooke
country: Canada
facility: Centre Hospitalier Universitaire de Sherbrooke
state: Quebec
city: København
country: Denmark
facility: Rigshospitalet
city: Bordeaux
country: France
facility: Institut Bergonie
city: Lille
country: France
facility: Centre Oscar Lambret
city: Lyon
country: France
facility: French Lyon Cancer Center
city: Paris
country: France
facility: APHP, Tenon Hospital in Paris
city: Stavrakia
country: Greece
facility: University General Hospital of Heraklion
state: Crete
city: Athens
country: Greece
facility: Laso General Hospital, First Department of Medical Oncology
city: Debrecen
country: Hungary
facility: Debrecen University Dep. of Oncology
city: Dublin 8
country: Ireland
facility: St. James's Hospital
city: Dublin
country: Ireland
facility: St Vincent's University Hospital
city: Galway
country: Ireland
facility: Galway University Hospital
city: Limerick
country: Ireland
facility: University Hospital Limerick
city: Waterford
country: Ireland
facility: University Hospital Waterford
city: Jerusalem
country: Israel
facility: Shaare Zedek Medical Center
city: Tel Hashomer
country: Israel
facility: Chaim Sheba Medical Center
city: Prato
country: Italy
facility: Ospedale di Prato
state: Firenze
city: Carpi
country: Italy
facility: U.O Medicina Oncologica Ospedale di Carpi
state: Modena
city: Castellanza
country: Italy
facility: Multimedica Spa
state: Vareze
city: Aviano
country: Italy
facility: Centro di Riferimento Oncologico
city: Biella
country: Italy
facility: Ospedale degli Infermi - S. C. Oncologia Medica
city: Bolzano
country: Italy
facility: Azienda Sanitaria di Bolzano
city: Genova
country: Italy
facility: Istituto Nazionale Ricerca Cancro
city: Meldola
country: Italy
facility: Istituto scientifico Romagnolo per lo studio e la cura
city: Milan
country: Italy
facility: Istituto Europeo di Oncologia (IEO)
city: Novara
country: Italy
facility: University of Eastern Piedmont
city: Pavia
country: Italy
facility: Salvatore Maugeri Foundation - Medical Oncology Unit
city: Rimini
country: Italy
facility: UO Oncologia, Rimini Hospital
city: Rome
country: Italy
facility: Regina Elena National Cancer Institute
city: Trento
country: Italy
facility: Ospedale di Trento
city: Varese
country: Italy
facility: AO Universitaria Ospedale Di Circolo e Fondazione
city: Viterbo
country: Italy
facility: Ospedale Belcolle di Viterbo
city: Amagasaki
country: Japan
facility: Kansai Rosai Hospital
state: Hyogo
city: Hamamatsu
country: Japan
facility: Seirei Hamamatsu General Hospital
state: Shizuoka
city: Fukuoka
country: Japan
facility: NHO Kyushu Cancer Centre, 3-1-1 Notame Minami-ku Fukuoka-shi
city: Kagoshima
country: Japan
facility: Social Medical Corporation Hakuaikai Sagara Hospital
city: Kawasaki
country: Japan
facility: St Marianna University School of Medicine Hospital
city: Kyoto
country: Japan
facility: Kyoto University Hospital
city: Matsuyama
country: Japan
facility: NHO Shikoku Cancer Center
city: Minato-ku, Tokyo
country: Japan
facility: Toranomon Hospital
city: Nagoya
country: Japan
facility: Kamiiida Daiichi General Hospital
city: Okayama
country: Japan
facility: Okayama University Hospital
city: Sendai
country: Japan
facility: Tohoku University Hospital
city: Tokyo
country: Japan
facility: National Cancer Center for Global Medicine
city: Tokyo
country: Japan
facility: National Cancer Center Hospital
city: Tokyo
country: Japan
facility: Showa University Hospital
city: Tokyo
country: Japan
facility: St Luke's International Hospital
city: Tokyo
country: Japan
facility: The Cancer Institute Hospital of JFCR
city: Tsukuba
country: Japan
facility: University of Tsukuba
city: Ōsaka
country: Japan
facility: NHO Osaka National Hospital
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
city: Beirut
country: Lebanon
facility: American University of Beirut Medical Center
city: Leiden
country: Netherlands
facility: Leiden University Medical Centre, Albinusdreef 2, Postbus 9600
city: Oslo
country: Norway
facility: Norwegian Radium Hospital (Oslo University)
city: Lisbon
country: Portugal
facility: Champalimaud Cancer Center - Breast Cancer Unit
city: Belgrade
country: Serbia
facility: Institute of Oncology & Radiology of Serbia
city: Ljubljana
country: Slovenia
facility: Institute of Oncology Ljubljana - Medical Oncology Department
city: El Palmar
country: Spain
facility: Hospital Clinico Universitario Virgen de la Arrixaca
state: Murcia
city: Barcelona
country: Spain
facility: Hospital Universitario Vall d'Hebron
city: Barcelona
country: Spain
facility: Hospital General de Catalunya
city: Donostia
country: Spain
facility: Hospital Universitario Donostia
city: Gerona
country: Spain
facility: Instituto Catalán de Oncología de Gerona Hospital
city: Madrid
country: Spain
facility: Hospital Universitario HM Sanchinarro - Centro Integral Oncologico Clara Campal (CIOCC)
city: Madrid
country: Spain
facility: Hospital Clinico San Carlos
city: Madrid
country: Spain
facility: Hospital Universitario de Fuenlabrada
city: Málaga
country: Spain
facility: Hospital Clinico Universitario Virgen de la Victoria
city: Oviedo
country: Spain
facility: Hospital Universitario Central de Asturias
city: Palma
country: Spain
facility: Hospital Son Espases, Palma de Mallorca
city: Pamplona
country: Spain
facility: Complejo Hospitalario de Navarra
city: Santiago de Compostela
country: Spain
facility: Complejo Hospitalario Universitario de Santiago
city: Sevilla
country: Spain
facility: Universitario Virgen del Rocio
city: Sevilla
country: Spain
facility: Hospital Quiron Sagrado Corazon
city: Toledo
country: Spain
facility: Hospital Virgen De La Salud
city: Valencia
country: Spain
facility: Hospital General Universitario de Valencia - Servico Oncologia
city: Zaragoza
country: Spain
facility: Hospital Clinico Universitario Lozano Blesa
city: Thun
country: Switzerland
facility: Spital STS AG Onkologiezentrum Thun-Berner Oberland
state: Bern
city: Baden
country: Switzerland
facility: Kantonspital Baden AG
city: Basel
country: Switzerland
facility: Universitätsspital Basel
city: Bellinzona
country: Switzerland
facility: Istituto Oncologico della Svizzera Italiana (IOSI)
city: Bern
country: Switzerland
facility: Inselspital Bern
city: Bern
country: Switzerland
facility: Oncocare Bern
city: Frauenfeld
country: Switzerland
facility: Brustzentrum Thurgau - Obstetrics and Gynecology
city: Genève
country: Switzerland
facility: University Hospital Geneva
city: Lausanne
country: Switzerland
facility: University Hospital of Lausanne (CHUV) BH06 - Oncology Department
city: Sion
country: Switzerland
facility: CHCVs Hôpital de Sion - Service d'oncologie ambulatoire
city: St. Gallen
country: Switzerland
facility: Brustzentum Kantonsspital St. Gallen
city: Zurich
country: Switzerland
facility: University Hospital Zurich
city: Zürich
country: Switzerland
facility: Brust-Zentrum AG
Study officials:
affiliation: Oncology Institue of Southern Switzerland (IOSI)
name: Olivia Pagani, MD
role: STUDY_CHAIR
References:
citation: Brinton LA, Sherman ME, Carreon JD, Anderson WF. Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst. 2008 Nov 19;100(22):1643-8. doi: 10.1093/jnci/djn344. Epub 2008 Nov 11.
citation: Leclere B, Molinie F, Tretarre B, Stracci F, Daubisse-Marliac L, Colonna M; GRELL Working Group. Trends in incidence of breast cancer among women under 40 in seven European countries: a GRELL cooperative study. Cancer Epidemiol. 2013 Oct;37(5):544-9. doi: 10.1016/j.canep.2013.05.001. Epub 2013 Jun 12.
citation: Bentzon N, During M, Rasmussen BB, Mouridsen H, Kroman N. Prognostic effect of estrogen receptor status across age in primary breast cancer. Int J Cancer. 2008 Mar 1;122(5):1089-94. doi: 10.1002/ijc.22892.
citation: Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008 Jul 10;26(20):3324-30. doi: 10.1200/JCO.2007.14.2471.
citation: Perachino M, Poggio F, Arecco L, Blondeaux E, Spinaci S, Marrocco C, Levaggi A, Lambertini M. Update on Pregnancy Following Breast Cancer Diagnosis and Treatment. Cancer J. 2022 May-Jun 01;28(3):176-182. doi: 10.1097/PPO.0000000000000599.